title: Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment.
abstract: OBJECTIVE
  In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma.
  
  
  METHODS
  Between January 1976 and December 1999, 165 select patients with T1G3 bladder tumors were conservatively treated with transurethral resection plus adjuvant intravesical therapy. Patients with concomitant or previous Tis, previous T1G3, tumor size greater than 3 cm and more than 3 lesions were excluded from analysis. Repeat transurethral resection was not routinely performed. However, cytology had to be negative for atypia before the start of adjuvant intravesical therapy.
  
  
  RESULTS
  Recurrence-free survival at 1, 3 and 5 years was 71.8%, 55.6% and 45%, respectively. Of the cases 14 (8.4%) progressed with a median progression-free survival of 149 months. A total of 23 patients (14%) died. The 5-year recurrence-free survival rate was 52%, 34% and 15% in cases of single and/or primary, multiple and recurrent tumors, respectively. Median overall survival was 144 months. The 5-year disease-free overall survival rate was 85%, 83%, 79% and 69% in cases of primary, single, multiple and recurrent tumors, respectively. An intact bladder was maintained in 137 patients (83%) with a mean disease-free overall survival of 102.7 months. Patients with recurrent and/or multiple T1G3 tumors showed worse survival (p = 0.0021 and 0.0142, respectively).
  
  
  CONCLUSIONS
  History and multiplicity are relevant predictors of survival even in highly selected patients with TIG3 bladder tumors that are conservatively treated.
authors.affiliation: Department of Internal Medicine, Cardiovascular and Nephro-Urological Diseases (Section of Urology), University of Palermo, Palermo, Italy. vserretta@libero.it
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Serretta
authors.forename: Antonina
authors.initials: A
authors.lastname: Ruggirello
authors.forename: Nino
authors.initials: N
authors.lastname: Dispensa
authors.forename: Rosalinda
authors.initials: R
authors.lastname: Allegro
authors.forename: Federico
authors.initials: F
authors.lastname: Aragona
authors.forename: Darvinio
authors.initials: D
authors.lastname: Melloni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D018579:Patient Selection; D011237:Predictive Value of Tests; D012307:Risk Factors; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013520:Urologic Surgical Procedures / Q000379:methods